Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q96IJ6

UPID:
GMPPA_HUMAN

ALTERNATIVE NAMES:
GDP-mannose pyrophosphorylase A; GTP-mannose-1-phosphate guanylyltransferase alpha

ALTERNATIVE UPACC:
Q96IJ6; A6NJ74; A8K3Q6; B3KMT4; Q53GI0; Q9NWC3; Q9Y5P5

BACKGROUND:
GDP-mannose pyrophosphorylase A, known alternatively as GTP-mannose-1-phosphate guanylyltransferase alpha, is integral to the synthesis of GDP-mannose. This compound is a cornerstone of glycosylation processes, affecting protein and lipid functionality. Its regulatory function and feedback inhibition mechanism by GDP-mannose highlight its importance in cellular metabolism.

THERAPEUTIC SIGNIFICANCE:
This protein's malfunction is associated with a rare autosomal recessive disorder characterized by a trio of symptoms: alacrima, achalasia, and intellectual disability. Exploring the function of GDP-mannose pyrophosphorylase A offers promising avenues for developing treatments for this syndrome and potentially other glycosylation-related diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.